AC Immune SA ACIU
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.13M | 423.10K | 1.58M | 1.10M | 1.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.13M | 423.10K | 1.58M | 1.10M | 1.10M |
| Cost of Revenue | 13.26M | 13.30M | 20.40M | 17.70M | 17.70M |
| Gross Profit | 5.87M | -12.87M | -18.81M | -16.60M | -16.60M |
| SG&A Expenses | 4.48M | 5.25M | 4.72M | 4.94M | 4.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -121.50K | -91.40K | -26.70K | 1.10K | 1.10K |
| Total Operating Expenses | 17.62M | 18.46M | 25.09M | 22.65M | 22.65M |
| Operating Income | 1.51M | -18.03M | -23.50M | -21.55M | -21.55M |
| Income Before Tax | 2.37M | -17.99M | -25.69M | -21.17M | -21.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.37M | -17.99M | -25.69M | -21.17M | -21.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.37M | -17.99M | -25.69M | -21.17M | -21.17M |
| EBIT | 1.51M | -18.03M | -23.50M | -21.55M | -21.55M |
| EBITDA | 1.86M | -17.62M | -23.06M | -21.15M | -21.15M |
| EPS Basic | 0.02 | -0.18 | -0.26 | -0.21 | -0.21 |
| Normalized Basic EPS | 0.01 | -0.11 | -0.16 | -0.13 | -0.13 |
| EPS Diluted | 0.02 | -0.18 | -0.26 | -0.21 | -0.21 |
| Normalized Diluted EPS | 0.01 | -0.11 | -0.16 | -0.13 | -0.13 |
| Average Basic Shares Outstanding | 105.25M | 101.07M | 100.63M | 100.41M | 100.41M |
| Average Diluted Shares Outstanding | 105.25M | 101.07M | 100.63M | 100.41M | 100.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |